| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
QX-314 Br is a novel intracellular blocker of NaV channels1-4 and a membrane impermeable quaternary analogue of lidocaine, a blocker of voltage-activated Na+ channels. QX 314 bromide also inhibits calcium currents in hippocampal CA1 pyramidal neurons.
| ln Vitro |
Transient receptor potential vanilloid subtype 1 (TRPV1) channels are subjected to biphasic effects by QX-314 bromide in vitro [1]. TRPV1 is immediately activated by QX-314 bromide (1–60 mM) in a concentration-dependent manner [1]. Cell death and blackening of the oocyte membrane are caused by QX-314 bromide (≥ 30 mM) [1]. In hippocampal CA1 pyramidal neurons, QX-314 bromide suppresses intracellular calcium currents, resulting in low-threshold (T-type) Ca2+ currents that average less than 10% of the control amplitude [3]. Because QX-314 bromide contains intracellular Br-, it causes a shift in the current-voltage relationship (IV) toward a positive voltage [3].
|
|---|---|
| ln Vivo |
QX-314 bromide (1.6 mg/kg; ic) eliminates reactions to painful mechanical and thermal stimuli when combined with capsaicin without causing impairments to motor or tactile function [2].
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (250-290 g) [2]
Doses: 1.6 mg/kg Route of Administration: intradermal injection Experimental Results: Response to noxious mechanical and thermal stimuli was eliminated when co-treated with capsaicin , without motor or tactile deficits. |
| References |
[1]. Rivera-Acevedo RE, et al. The quaternary lidocaine derivative, QX-314, exerts biphasic effects on transient receptor potential vanilloid subtype 1 channels in vitro. Anesthesiology. 2011 Jun;114(6):1425-34.
[2]. Binshtok AM, et al. Coapplication of lidocaine and the permanently charged sodium channel blocker QX-314 produces a long-lasting nociceptive blockade in rodents. Anesthesiology. 2009 Jul;111(1):127-37. [3]. Talbot MJ, et al. Intracellular QX-314 inhibits calcium currents in hippocampal CA1 pyramidal neurons. J Neurophysiol. 1996 Sep;76(3):2120-4. |
| Molecular Formula |
C16H27BRN2O
|
|---|---|
| Molecular Weight |
343.30238
|
| CAS # |
24003-58-5
|
| Related CAS # |
QX-314 chloride;5369-03-9
|
| SMILES |
CC[N+](CC)(CC(NC1=C(C)C=CC=C1C)=O)CC.[Br-]
|
| InChi Key |
DLHMKHREUTXMCH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H26N2O.BrH/c1-6-18(7-2,8-3)12-15(19)17-16-13(4)10-9-11-14(16)5/h9-11H,6-8,12H2,1-5H31H
|
| Chemical Name |
N-(2,6-Dimethylphenylcarbamoylmethyl)triethylammonium bromide
|
| Synonyms |
QX-314 Br QX-314Br QX314 Br QX 314 QX314.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~291.29 mM)
DMSO : ~50 mg/mL (~145.65 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (145.65 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9129 mL | 14.5645 mL | 29.1290 mL | |
| 5 mM | 0.5826 mL | 2.9129 mL | 5.8258 mL | |
| 10 mM | 0.2913 mL | 1.4565 mL | 2.9129 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA